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The objective of this study was to investigate the effect of equine arteritis virus (EAV) on type I interferon (IFN) production. Equine
endothelial cells (EECs) were infected with the virulent Bucyrus strain (VBS) of EAV and expression of IFN-𝛽 was measured at
mRNA and protein levels by quantitative real-time RT-PCR and IFN bioassay using vesicular stomatitis virus expressing the green
fluorescence protein (VSV-GFP), respectively. Quantitative RT-PCR results showed that IFN-𝛽mRNA levels in EECs infected with
EAVVBS were not increased compared to those in mock-infected cells. Consistent with quantitative RT-PCR, Sendai virus- (SeV-)
induced type I IFNproductionwas inhibited by EAV infection. Using an IFN-𝛽 promoter-luciferase reporter assay, we subsequently
demonstrated that EAV nsps 1, 2, and 11 had the capability to inhibit type I IFN activation. Of these three nsps, nsp1 exhibited the
strongest inhibitory effect. Taken together, these data demonstrate that EAV has the ability to suppress the type I IFN production
in EECs and nsp1 may play a critical role to subvert the equine innate immune response.
1. Introduction
Equine arteritis virus (EAV) is the causative agent of equine
viral arteritis, a respiratory and reproductive disease of horses
[1, 2]. EAV is a small enveloped virus with a positive-sense,
single-stranded RNA genome of ∼12.7 kb. It belongs to the
family Arteriviridae (genus Arterivirus, order Nidovirales),
which also includes porcine reproductive and respiratory
syndrome virus (PRRSV), simian hemorrhagic fever virus
(SHFV), and lactate dehydrogenase-elevating virus (LDV) of
mice [3–5]. The EAV genome includes at least ten known
functional open reading frames (ORFs 1a, 1b, 2a, 2b, 3,
4, 5a, 5b, 6, and 7) [5–7]. ORFs 1a and 1b are located
at the 5󸀠-proximal three-quarters of the genome and are
translated to produce replicase polyproteins pp1a and pp1ab
(1,727 and 3,175 amino acids, resp.). Translation of ORF1b
depends on a −1 ribosomal frameshift located just before
termination of ORF1a translation [8]. The two replicase
precursor polyproteins are cleaved by three ORF1a-encoded
proteases that reside in nsp1, nsp2, and nsp4, yielding at least
13 end-products, namely, nonstructural proteins (nsps) 1 to
12, including a recently described nsp7𝛼 and 7𝛽 [5, 9, 10].
The remaining eight ORFs (2a, 2b, and 3, 4, 5a, 5b, and 6-7)
are located in the 3󸀠 quarter of the genome and encode the
structural proteins (E, GP2, GP3, GP4, ORF5a protein, GP5,
M, and N, resp.) of the virus [5, 6, 11–13].
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Type I interferon (IFN-𝛼/𝛽) is a key component of the
host innate immune response to viral infection [14]. Recog-
nition of pathogen-associated molecular patterns (PAMPs)
in double-stranded RNA (dsRNA) by intracellular receptors,
such as retinoic acid inducible gene I (RIG-I) and melanoma
differentiation-associated antigen 5 (MDA-5) [15], activates
protein signaling cascades that result in the activation of
transcription factors, including interferon regulatory factor-
3 (IRF-3) and nuclear factor-𝜅B (NF-𝜅B) [14]. The IFN-
𝛽 promoter contains positive regulatory domains (PRDs),
including the binding sites for different transcription factors,
IRF-3 (PRDs I and III) and NF-𝜅B (PRD II). Activation
of these transcription factors triggers the formation of
enhanceosomes in the cell nucleus and induces the expres-
sion of IFN-𝛼/𝛽 [14, 16]. Both IRF-3 and NF-𝜅B activation
are mediated by mitochondrial antiviral signaling (MAVS)
protein, which functions downstream of RIG-I and MDA-5
and upstream of the I𝜅B kinase (IKK) complex and TANK-
binding kinase-1 (TBK1) [17–20]. Among the various factors
involved in type I IFN production, IRF-3 plays a critical
role. IRF-3 is expressed in most cell types and resides in
the cytoplasm in an inactive form. When stimulated, IRF-
3 becomes phosphorylated and undergoes conformational
changes, resulting in dimerization with the exposure of
nuclear localization signal. In the nucleus, IRF-3 recruits
coactivator CBP/p300 and forms a complex to bind IRF-3
responsive elements (PRDs I and III) of the IFN-𝛽 promoter
[14]. In addition to IRF-3, NF-𝜅B is also a critical regulator
of host innate and adaptive immunity. It plays an important
role in the regulation of cell proliferation as well as cell
survival. Many viruses have evolved strategies to counteract
key elements of the IFN response and prevent development
of an antiviral response in the host [14]. Through evolution,
viruses can either activate or inhibit the NF-𝜅B pathway in
order to replicate in host cells. Viruses such as African swine
fever virus and influenza A virus block NF-𝜅B activation
to counteract the host innate immune response [21, 22].
In contrast, viruses such as hepatitis C virus, reovirus, and
herpes simplex virus have developed mechanisms to directly
activate NF-𝜅B to support production of progeny viruses and
intracellular spreading [23–25].
Until now, the innate immune response to EAV infection
was poorly characterized and the information pertaining
to type I IFN production was largely derived from studies
of PRRSV and other nidoviruses [26–32]. Recently, van
Kasteren et al. [33] reported that the EAV PLP2 has de-
ubiquitylation function which suppresses RIG-I to control
innate immune signaling in EAV-infected cells [34, 35].
In all these studies, the investigators have used recombi-
nant proteins (e.g., nsp2 protein of EAV) and a specific
immune suppression mechanism. However, the effect of
the whole virus and involvement of other EAV proteins
in the suppression of host cell immune responses are
largely unknown. To elucidate the molecular mechanism
of EAV involved in host immune suppression, the objec-
tive of this study was to investigate the effect of EAV on
type I IFN production and to further identify the specific
viral proteins responsible for the suppression of IFN-𝛽
activity.
2. Materials and Methods
2.1. Virus and Cells. Equine pulmonary artery endothe-
lial cells (EECs [36]), baby hamster kidney-21 (BHK-21
[ATCCCCL-10],Manassas,VA), andHEK293T (ATCCCRL-
11228) cells were maintained in Dulbecco’s modified essen-
tial medium (Mediatech, Herndon, VA) supplemented with
10% fetal bovine serum (FBS; HyClone Laboratories, Inc.,
Logan, UT), 100U/𝜇g per mL penicillin-streptomycin, and
200mM L-glutamine (Gibco, Carlsbad, CA) in a humidified
incubator with 5% CO
2
at 37∘C. HeLa cells (NIH AIDS
Research and Reference Reagent Program, Germantown,
MD)were propagated inminimumessentialmedium (MEM)
supplemented with 10% heat-inactivated FBS in a humidified
incubator with 5% CO
2
at 37∘C. MDBK (ATCC CCL-22)
cells were grown in Eagle’s minimum essential medium with
10% ferritin-supplemented bovine calf serum (HyClone Lab-
oratories, Inc., Logan, UT) and 100U/𝜇g per mL penicillin-
streptomycin (Gibco, Carlsbad, CA). The virulent Bucyrus
strain of EAV (EAV VBS, horse passage 15 pleural fluid;
ATCC VR-796, Manassas, VA) was passaged once in EECs
to obtain high-titered working stocks for the present study
using the method described previously [37]. Sendai virus,
the Cantell strain (SeV; ATCC VR-907, Manassas, VA), was
propagated in embryonated chicken eggs. The virus titer was
determined by hemagglutination inhibition (HI) assay using
chicken red blood cells as described previously [38]. Vesicular
stomatitis virus expressing green fluorescent protein (VSV-
GFP [39]) was kindly provided by Dr. Adolfo Garcia-Sastre
(Mt. Sinai School of Medicine, New York, NY).
2.2. Plasmids. Plasmids for expression of recombinant EAV
nsp1 to nsp12 in mammalian cells were constructed as
previously described [40]. Briefly, the coding regions of
each of the twelve nsps were PCR-amplified from the EAV
rVBS full-length infectious cDNA clone [41] and cloned into
the eukaryotic expression vector pCAGGS [33]. The nsp5,
nsp6, nsp10, and nsp12 were expressed as C-terminal FLAG-
tagged fusion proteins. To express the recombinant EAVnsps,
BHK-21 cells were transfected with each individual plasmid
containing an nsp coding region. Transfectionwas performed
using FuGENE HD (Promega, Madison, WI) according to
manufacturer’s instructions. The specificity of each recom-
binant protein was confirmed by immunofluorescence and
Western blot analysis. Reporter plasmids expressing the
firefly luciferase under the control of either the IFN-𝛽 pro-
moter (p125-Luc) or an artificial promoter containing three
IRF-3 binding sites (p55-CIB-Luc) were kindly provided by
Yoneyama et al. [42]. The pNF-𝜅B-Luc reporter plasmid
(Stratagene, La Jolla, CA) expresses the firefly luciferase under
the control of a promoter with NF-𝜅B-response element.
The pRL-SV40 plasmid (Promega, Madison, WI) expresses a
Renilla luciferase under the control of a simian virus (SV40)
promoter.The pEFneo-RIG-I, pEFneo-MDA-5, and pEFneo-
IKK𝜀 were kindly provided by Komatsu et al. [43]. The
pcDNA3-TRIF and pCMV2-IKK2-WT were purchased from
Addgene (Cambridge, MA). Construction of the pCAGGS-
IRF-3 and pCAGGS-NS1 plasmids was described previously
[44].
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2.3. Antibodies. To detect EAV antigens in infected cells,
monoclonal antibodies (MAbs) against EAV nsp1 (MAb
12A4) and N protein (MAb 3E2) were used [45, 46]. Spe-
cific polyclonal rabbit antisera recognizing EAV nsp2 [47],
nsp3 [48], nsp4 [47], nsp7-8 [47], and nsp10 [49] have
been described previously. In addition, antisera against nsp9
and nsp11 were raised by immunizing rabbits with purified
full-length recombinant proteins expressed in E. coli (J.C.
Zevenhoven, D. D. Nedialkova, and E. J. Snijder, unpublished
data). Anti-FLAG MAb (F3165) purchased from Sigma (St.
Louis, MO) was used to detect FLAG-tagged EAV fusion
proteins in immunofluorescence assay. Rabbit polyclonal
antibodies for human IRF-3 (sc-9082) and NF-𝜅B p65 (sc-
7151) were purchased from Santa Cruz Biotechnologies Inc.
(Santa Cruz, CA). Alexa Fluor 488-conjugated and Alexa
Fluor 594-conjugated secondary antibodies were purchased
from Invitrogen (Carlsbad, CA).
2.4. RNA Extraction and Quantitative Real-Time RT-PCR
(qRT-PCR). Total RNA was extracted using MagMAX-96
Total RNA Isolation kit (Ambion, Austin, TX) in a MagMAX
Express-96magnetic particle processor (Applied Biosystems,
Foster City, CA). RNA from each culture was treated with
DNase to remove any contaminating genomic DNA (gDNA).
The RNA concentration was assessed at OD
260 nm and purity
was verified by the OD
260
/OD
280
ratio using NanoDrop
(Thermo Scientific, Wilmington, DE). The reverse transcrip-
tion reaction was performed with 1 𝜇g of total RNA using
RT random primers and a MultiScribe reverse transcriptase
(High Capacity cDNA Reverse Transcription kit with RNase
inhibitor (Applied Biosystems, Foster City, CA)) according
to the manufacturer’s instructions. The following IFN-𝛽
primers and probe set were used for PCR amplification with
an Applied Biosystems 7500 Fast Real-Time PCR System:
EqIL-IFN-𝛽F: 5󸀠-AATGGCCCTCCTGCTGTGT-3󸀠, EqIL-
IFN-𝛽R: 5󸀠-CCGAAGCAAGTCATAGTTCACAGA-3󸀠, and
EqIL-IFN-𝛽: probe 5󸀠-FAM-CTCCACCACGGCTC-NFQ-
3󸀠. For each sample, cDNA corresponding to the 𝛽-
glucuronidase (𝛽-GUS) gene was amplified and used as
an endogenous control. All PCR efficiency values were
determined using LinReg [50]. The relative concentration
of target gene mRNA was equal to 2−ΔΔC𝑡 where ΔΔC
𝑡
= [(Avg. gene of interest C
𝑡
− Avg. 𝛽-GUS C
𝑡
)sample −
(Avg. gene of interest C
𝑡
−Avg. 𝛽-GUS C
𝑡
)calibrator].The cal-
ibrator was calculated from the mean ΔC
𝑡
of mock-infected
samples for each individual gene.
2.5. Interferon Bioassay. The interferon bioassay was per-
formed using a recombinant vesicular stomatitis virus (VSV)
that expresses green fluorescent protein (VSV-GFP) as previ-
ously described [31, 39, 51]. Briefly, EECs were either infected
with EAV or Sendai virus (SeV) alone or dually infected
with both EAV and SeV at an m.o.i. of 1 and incubated
for 24 h at 37∘C. Culture supernatants were collected and
virus in supernatant was inactivated by ultraviolet (UV)
irradiation for 30min. Two-fold dilutions of supernatants
were made in DMEM and used in IFN bioassays. MDBK
cells were grown in 96-well plates to 70% confluency and
incubatedwith two-fold dilutions of each of the supernatants.
After 24 h incubation at 37∘C, cells were infected with VSV-
GFP at an m.o.i. of 0.1 and further incubated for 18 h. Cells
were fixed with 4% paraformaldehyde and expression of
green fluorescence protein was examined under an inverted
fluorescence microscope.
2.6. Cytotoxicity Test of EAV nsp1 on HEK293T Cells. HEK-
293T cells in 96-well plates were transfected with increased
amount of plasmid expressing EAV nsp1 (0, 0.05, 0.1, 0.2,
or 0.4 𝜇g/well) using FuGENE HD (Promega, Madison, WI)
transfection reagent (0.8 𝜇L/well). At 24 h after transfection,
cytotoxicity was determined by using a cell proliferation
assay (CellTiter 96 Aqueous One Solution, Life Technologies,
Grand Island, NY).
2.7. Luciferase Reporter Assay. HEK293T cells were seeded
in 24-well plates and transfected with various combina-
tions of plasmid DNAs: the pEFneo-RIG-I, pEFneo-MDA-
5, pEFneo-IKK𝜀, pcDNA3-TRIF, or pCAGGS-IRF-3 was
mixed with a plasmid expressing an EAV protein (or empty
pCAGGS vector), a luciferase reporter plasmid, and the pRL-
SV40 plasmid. Transfection was performed using FuGENE
HD (Promega, Madison, WI) transfection reagent following
the manufacturer’s instruction. For the SeV or IFN stim-
ulation, HEK293T cells were transfected with a plasmid
expressing an EAV protein (or empty pCAGGS vector), a
reporter plasmid, and the pRL-SV40 plasmid. The plasmid
pCAGGS-NS1 expressing swine influenza virus NS1 was used
as positive control. At 20 h after transfection, cells were
infected with SeV at 5000HA unit/0.5mL/well for 12–16 h
or induced by treatment with 2000 IU/0.5mL/well of IFN-
𝛼 or IFN-𝛽 for 16 h. Cells were harvested at the indicated
time points. Cell lysates were subjected to reporter gene assay
using the dual luciferase reporter system (Promega,Madison,
WI) according to manufacturer’s instruction. Firefly and
Renilla luciferase activities were measured in a luminometer
(Berthold Technologies, Oak Ridge, TN). Values for each
sample were normalized using the Renilla luciferase values.
Relative luciferase (RLU) activity is defined as the ratio of
firefly luciferase reporter activity to Renilla luciferase activity.
2.8. Immunofluorescence Assay. Cells were seeded on cov-
erslips and grown to 80% confluency. DNA transfection
was performed in HeLa cells using Lipofectamine 2000
(Invitrogen; Carlsbad, CA) according to the manufacturer’s
instructions. A transfection mix containing DNA and Lipo-
fectamine 2000 in OPTI-MEM I (Invitrogen; Carlsbad, CA)
was incubated at room temperature for 20min and added
to each well. After incubation, the transfection mix was
replaced with fresh medium, and cells were incubated for
12 h to allow gene expression. For IRF-3 staining, cells
were stimulated with 1 𝜇g/mL of polyinosinic:polycytidylic
[(poly(I:C)]; Sigma, St. Louis, MO) or untreated for 8 h. For
NF-𝜅B p65 staining, HeLa cells were treatedwith 20 ng/mL of
TNF-𝛼 for 45min or untreated. After incubation, cells were
washed with phosphate-buffered saline (PBS), fixed with 4%
paraformaldehyde for 10min at room temperature (RT), and
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then permeabilized using 0.1% Triton X-100 for 10min at
RT. After blocking with 1% bovine serum albumin (BSA) in
PBS for 30min, cells were incubated with primary antibody
in PBS containing 1% BSA for 2 h followed by incubation
with Alexa Fluor 488- and/or Alexa Fluor 594-conjugated
secondary antibody for 1 h. Nuclear staining was performed
withDAPI (4󸀠,6-diamidino-2-phenylindole; Sigma, St. Louis,
MO) for 3min at RT. After washing with PBS, coverslips
were mounted onto microscope slides using Fluoromount-G
mountingmedium (Southern Biotech, Birmingham, AL) and
examined under the fluorescencemicroscope (Leitz Laborlux
12).
3. Results
3.1. Suppression of Type I Interferon Production by EAV. To
investigate the effect of EAV on type I IFN production, IFN-
𝛽 mRNA expression in infected cells was analyzed using
qRT-PCR. Equine pulmonary endothelial cells (EECs) were
infected with EAV VBS at an m.o.i. of 5 for 8 h, followed
by infection with SeV for 3 or 6 hpi. SeV-alone-infected
cells were used as positive control for type I IFN induction
and mock-infected cells were used as negative control. As
shown in Figure 1(a), IFN-𝛽 mRNA was barely detected
in cells infected with EAV alone, whereas SeV infection
induced a strong expression, approximately 190–200-fold
increase of IFN-𝛽 mRNA expression level in comparison
to that of mock-infected cells at 3 or 6 hpi. In contrast,
SeV-induced IFN-𝛽 mRNA expression, at both 3 and 6 hpi,
was significantly suppressed in cells previously infected with
EAV. In parallel with the quantitative measurement of IFN-
𝛽 mRNA, EAV-induced suppression of IFN production was
confirmed by IFN bioassay using VSV-GFP, since VSV is IFN
sensitive and presence of IFN-𝛼/𝛽 blocks VSV replication.
EECs were either infected with EAV or SeV alone or infected
with both EAV and SeV. Mock-infected cells were used as
negative control. Subsequently, MDBK cells were incubated
with two-fold serial dilutions of virus-inactivated cell culture
supernatant and then infected with VSV-GFP. The VSV
infectivity was determined by monitoring the level of GFP
expression. As shown in Figure 1(b), VSV-GFP replicatedwell
in cell culture supernatant from mock-infected cells, while
VSV replication was effectively inhibited in those MDBK
cells that were preincubated with supernatant from SeV-
infected EECs. NoVSV-GFP replication was observed up to a
dilution of 1 : 32 of the culture supernatant from SeV-infected
cells. In contrast, VSV-GFP replication was not inhibited
in MDBK cells that were preincubated with cell culture
supernatant from EECs infected with EAV alone. Consistent
with quantitative RT-PCR results, SeV-induced type I IFN
productionwas significantly inhibited by EAV exposure since
VSV-GFP replication was detected at a lower level compared
to that from EECs only infected with SeV. Taken together, the
data suggest that EAV has an ability to suppress the induction
of IFN in infected cells.
3.2. EAV nsp1, nsp2, and nsp11 Exhibited Strong Inhibition
on IFN-𝛽 Promoter Activation. To investigate the role of
EAV proteins as potential IFN antagonists, we focused on
the nonstructural proteins of EAV. Each of the 12 nsp-
encoding regions from the genome of EAV VBS was cloned
individually into a mammalian expression vector, pCAGGS
[40]. The expression of recombinant proteins in the plasmid
DNA transfected cells was verified by immunofluorescence
assay (Figure 2(a)). To determine whether these nsps have
an effect on IFN-𝛽 activation, we used an IFN-𝛽 promoter-
luciferase reporter assay. HEK293T cells were cotransfected
with individual nsp-expressing plasmid and the luciferase
reporter plasmid (p125-Luc) along with a Renilla luciferase
expression plasmid (pRL-SV40) for normalizing purpose of
sample expression levels. As a positive control, pCAGGS-
NS1 plasmid expressing swine influenza virus NS1 (sw-ns1)
gene was used to cotransfect the cells with the reporter
plasmid, since sw-ns1 is a known IFN antagonist [52].
At 24 h after transfection, cells were infected with SeV to
induce luciferase production.The IFN-𝛽 promoter-luciferase
reporter assay result is presented in Figure 2(b). As we
expected, the expression of sw-ns1 significantly inhibited
IFN-𝛽 promoter-driven luciferase expression. In contrast,
a strong reporter signal was observed in cells transfected
with empty pCAGGS plasmid after infection with SeV. IFN-
𝛽 promoter activation by SeV infection was suppressed
to various degrees by expression of several EAV nsps,
among which nsp1, nsp2, and nsp11 showed strong inhi-
bition of IFN-𝛽 promoter-driven luciferase expression. In
particular, nsp1 exhibited the strongest inhibitory effect,
followed by nsp11 and nsp2. The results suggest that sev-
eral EAV nsps are capable of suppressing IFN-𝛽 promoter
activation.
3.3. EAV nsp1 Interferes with IRF-3- and NF-𝜅B-Mediated
Signaling Pathways for IFN-𝛽 Production. Since the nsp1 of
EAV showed the strongest inhibitory effect on the IFN-
𝛽 promoter activation, we further determined the specific
IFN production signaling pathway(s) associated with nsp1
expression. Toward this end, we tested nsp1 in IRF-3- and
NF-𝜅B-promoter-driven luciferase reporter systems. Cells
were cotransfected with control plasmids or with plasmids
expressing the EAV nsp1 protein, the plasmid pRL-SV40, and
a luciferase reporter plasmid.
As shown in Figure 3(a), upon SeV stimulation, the level
of IRF-3-dependent luciferase expression was significantly
reduced in cells expressing EAV nsp1 and sw-ns1 compared
to that in cells transfected with control plasmid (empty
pCAGGS vector). Similarly, NF-𝜅B promoter-dependent
luciferase expression was suppressed in cells expressing EAV
nsp1 (Figure 3(b)). These results suggest that EAV nsp1 sup-
presses IFN-𝛽 production by interfering with the IRF-3 and
NF-𝜅B signaling pathways. Furthermore, the viability of the
HEK293T cells expressing EAV nsp1 24 h after transfection
was compared to that of untransfected control cells. As shown
in Figure 3(c), the cell viability appeared to be not affected
by the nsp1 protein expression. These data further suggest
that the decreased type I IFN production is not due to
cellular cytotoxicity, which further confirmed the important
role of nsp1 in the interfering with IRF-3 andNF-𝜅B signaling
pathways.
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Figure 1: Inhibition of type I IFN production after EAV infection. (a) Expression levels of IFN-𝛽 mRNA in EAV infected cells. EECs were
mock-infected or infected with EAV VBS at an m.o.i. of 5 for 8 h. Subsequently, cells were infected with Sendai virus (SeV; 100HAU/mL)
for 3 h or 6 h. Total RNA was isolated and real-time RT-PCR was performed for the detection of equine IFN-𝛽. Bar graph showing relative
quantitation (RQ) values of IFN-𝛽mRNA expression from three independent experiments are shown. (b) VSV bioassay for IFN production.
EECs were mock-infected or infected with EAV VBS at an m.o.i. of 1 for 24 h. SeV was used as an IFN stimulator. Cell culture supernatants
were collected and UV-irradiated for 30min prior to use in the assay. MDBK cells were grown in 96-well plates and incubated with 2-fold
dilution series of the supernatant up to 1/32. After 24 h incubation, cells were infected with VSV-GFP at anm.o.i. of 0.1, and 18 h after infection
GFP expression was assessed by fluorescence microscopy. Each dilution was tested in duplicate.
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Figure 2: EAV nonstructural proteins (nsps) involved in suppression of IFN-promoter activation. (a) Expression of nsps in transfected cells
detected by indirect immunofluorescence assay. HEK293T cells were transfected with each EAV nsp and fixed at 24 h after transfection. Cells
were stained with EAV nsp1 MAb, EAV nonstructural protein-specific rabbit antisera (nsp2, nsp3, nsp4, nsp7-8, nsp9, nsp10, and nsp11), or
anti-FLAGmonoclonal antibody (nsp5, nsp6, and nsp12). DyLight 549-conjugated goat anti-rabbit antibody was used as secondary antibody.
(b) HEK293T cells were cotransfected with p125-Luc, pRL-SV40, and pCAGGS expressing nsps or pCAGGS empty vector for 24 h. Cells were
harvested and measured for firefly and Renilla luciferase activities. Relative luciferase (RLU) activity is defined as a ratio of firefly luciferase
reporter activity to Renilla luciferase activity. Each data point shown represents a mean value ± standard error of the mean (SEM) from three
experiments.
3.4. Effect of EAV nsp1 on the IRF-3-Dependent Signaling
Pathway. We further investigated specific steps in the IRF-
3 signaling pathway that EAV nsp1 could possibly block. We
tested each step in the signaling pathway of IRF-3 activa-
tion. First, we investigated whether the nsp1 was interfering
with the mitochondrial antiviral signaling (MAVS) complex
activity. Since MDA-5 or RIG-I is associated with the MAVS
complex, cells were cotransfected with a plasmid expressing
RIG-I, MDA-5, or MAVS protein, a plasmid expressing
EAV nsp1, the plasmid pRL-SV40, and the p55-CIB-Luc
reporter plasmid. As shown in Figures 4(a)–4(c), IRF-3
promoter-dependent luciferase expression was suppressed in
the presence of EAV nsp1. These results suggested that EAV
nsp1 might inhibit the MAVS-mediated IFN-𝛽 induction or
downstream portion of the signaling pathway. Therefore, we
further tested the effect of EAV nsp1 on TRIF- and IKK𝜀-
mediated IFN-𝛽 induction. The results showed that nsp1 had
the ability to suppress TBK1- and IKK𝜀-mediated reporter
gene expression (Figures 4(d) and 4(e)). Similarly, overex-
pression of IRF-3 itself did not activate the transcription of
the luciferase reporter gene either (Figure 4(f)).These results
suggest that EAV nsp1 might block the signaling process
downstream IRF-3 activation, possibly in the nucleus.
3.5. Effect of EAV nsp1 on the NF-𝜅B -Dependent Signaling
Pathway. Since EAV nsp1 also inhibited the activation of the
NF-𝜅B-dependent signaling pathway (Figure 3), the mech-
anism by which EAV nsp1 can inhibit the NF-𝜅B signaling
pathway was analyzed in detail. As shown in Figure 5(a), in
the presence of EAV nsp1, NF-𝜅B-dependent reporter gene
expression was strongly inhibited with the stimulation of
the TNF-𝛼, a potent inducer for the activation of NF-𝜅B
signaling pathway. Subsequently, the effect of EAV nsp1 on
the MAVS complex and Toll/interleukin-1 receptor domain-
containing adaptor protein (TRIF-) and IkB kinase beta
(IKK𝛽-) mediated NF-𝜅B activation was evaluated. Over-
expression of any of these proteins induced activation of
NF-𝜅B-dependent reporter gene expression. However, when
cells coexpressed the EAV nsp1 with one of these signaling
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Figure 3: EAV nsp1 inhibits both IRF-3 and NF-𝜅B pathways. HEK293T cells were cotransfected with reporter plasmid of (a) p55-CIB-
Luc and (b) NF-𝜅B-Luc and a plasmid that constitutively expresses Renilla luciferase and plasmids expressing EAV nsps or the indicated
control plasmids. Cells were infected with Sendai virus (SeV) at 24 hours post transfection. Cells were harvested and analyzed for firefly and
Renilla luciferase. Data were normalized using the Renilla luciferase values. Data are averages ± standard deviation for three experiments.
(c) Cytotoxicity test of EAV nsp1 on HEK293T cells. Graph shows the results (mean and SD) of a representative quadruplicate experiment.
Relative luciferase (RLU) activity is defined as a ratio of firefly luciferase reporter activity to Renilla luciferase activity.
molecules, the expression level of luciferase reporter was
significantly reduced (Figures 5(b)–5(d)). Similarly, over-
expression of p65, a subunit of the NF-𝜅B complex, had
no effect on the activation of the transcription of NF-𝜅B-
driven reporter gene, but EAV nsp1 significantly reduced the
expression level of luciferase reporter signal (Figure 5(e)).
3.6. Effect of EAV nsp1 Expression on Nuclear Transloca-
tion of IRF-3 and NF-𝜅B. The mechanism of EAV nsp1
effect on IRF-3- and NF-𝜅B-dependent gene expression
was further examined by observing the nuclear localization
of IRF-3 and NF-𝜅B, respectively. EAV nsp1 transfected
HeLa cells were stimulated with poly(I:C), and subsequently
expression of IRF-3 was stained with anti-IRF-3 antibody.
In the absence of stimulation, IRF-3 was homogeneously
distributed throughout the cell, whereas upon poly(I:C)
stimulation IRF-3 was mainly translocated into the nucleus.
As shown in Figure 6(a), expression of EAV nsp1 did not
block the nuclear translocation of IRF-3.The result suggested
that nsp1-mediated suppression of IFN production occurs
downstream of the IRF-3 nuclear translocation. Similarly,
the nuclear translocation of NF-𝜅B p65 subunit was deter-
mined in cells expressing EAV nsp1 by immunofluorescence
assay (Figure 6(b)). NF-𝜅B remained largely not only in
the cytoplasm but also in the nucleus to some extent in
unstimulated cells, whereas TNF-𝛼 stimulation induced the
nuclear translocation of p65. In cells expressing EAV nsp1,
TNF-𝛼 stimulation did not notably change the p65 nuclear
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Figure 4: EAV nsp1 inhibits the IRF-3 signaling pathway. Suppression of (a) RIG-I, (b) MDA-5, (c) MAVS, (d) TRIF, (e) IKK𝜀, and (f) IRF-3-
induced IRF-3 dependent reporter gene expression by EAV nsp1 in HEK293T cells. (a)–(f) Cells cultured in 24-well plates were cotransfected
with plasmid pEFneo-RIG-I, pEFneo-MDA-5, pEGFP-N1-MAVS, pcDNA3-TRIF, pEFneo-IKK𝜀, or pCAGGS-IRF-3 along with a pCAGGS
expressing nsp1 protein or pCAGGS empty vector, pRL-SV40, and a luciferase reporter plasmid p55-CIB-Luc for 24 h. Cells were harvested
and measured for firefly and Renilla luciferase activities. Relative luciferase (RLU) activity is defined as a ratio of firefly luciferase reporter
activity to Renilla luciferase activity. Mean value ± SEM from three experiments is shown.
translocation, and p65 normally remained in the nucleus,
indicating that EAV nsp1 did not block p65 nuclear translo-
cation. These results suggest that, in the NF-𝜅𝛽-dependent
signaling pathway for IFN-𝛽 production, the activation of
IFN-𝛽 transcription would be blocked by nsp1 somewhere
downstream in the nucleus after NF-𝜅B nuclear translocation
occurred.
4. Discussion
Synthesis and secretion of type I IFNs, such as IFN-𝛼 and
IFN-𝛽, are critical aspects of the antiviral immune response
[14, 53, 54]. Viruses use different mechanisms to inhibit
interferon response in order to evade the host innate immune
response. Many viruses encode more than one protein capa-
ble of inhibiting the interferon response, which act synergis-
tically to ensure complete blocking of interferon activity. For
example, Ebola, Nipah, and SARS-CoV encodemultiple viral
proteins capable of inhibiting interferon activity, suggesting
important roles for these proteins in pathogenesis and disease
outcome [55–58]. In this study, we investigated whether EAV
has the ability to interfere with the host innate immune
response, in particular, type I IFN production. Our results
demonstrated that EAV infection in EECs significantly inhib-
ited type I IFN production at both mRNA and protein levels,
whereas infection with SeV stimulated a high level of type
I IFN production. Furthermore, EAV infection significantly
inhibited SeV-induced type I IFN production as well. Based
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Figure 5: EAV nsp1 inhibits the NF-𝜅B signaling pathway. Suppression of (a) TNF-𝛼, (b) MAVS, (c) TRIF, (d) IKK𝛽, and (e) p65 subunit
of NF-𝜅B-induced NF-𝜅B-dependent reporter gene expression by EAV nsp1 in HEK293T cells. (a) Cells cultured in 24-well plates were
cotransfected with pNF-𝜅B-Luc, pRL-SV40, and pCAGGS expressing nsp1 or pCAGGS empty vector for 24 h and subsequently stimulated
with TNF-𝛼 (20 ng/mL) for 6 h. (b)–(e) Cells were cotransfected with plasmid pEGFP-N1-MAVS, pcDNA3-TRIF, pCMV2-IKK2-WT, or
pEGFP-N1-p65 along with a pCAGGS expressing nsp1 protein or pCAGGS empty vector, pRL-SV40, and a luciferase reporter plasmid pNF-
𝜅B-Luc for 24 h. Cells were harvested and measured for firefly and Renilla luciferase activities. Relative luciferase (RLU) activity is defined as
a ratio of firefly luciferase reporter activity to Renilla luciferase activity. Mean value ± SEM from three experiments is shown.
on IFN-𝛽 promoter-luciferase reporter assay results, three
EAV nonstructural proteins, nsp1, nsp2, and nsp11, were
identified as potential IFN antagonists. Previous studies
reported that EAV nsp2-encoded papain-like proteinase
(PLP2) is capable of inhibiting Ub- and ISG15-dependent
innate immune responses [34, 35, 59].TheEAVnsp11 encodes
NendoU endoribonuclease [60], which is highly cytotoxic
upon its in vitro expression. In PRRSV, the homologous nsp11
was proposed to be an IFN antagonist [26, 31, 61]. However,
whether this effect is due to the cytosolic version of the
enzyme targeting on the overall RNA population of the cell
or the specific suppression of IFN production needs to be
determined in the future. It could be possible that the three
potential immune antagonists of EAV, nsp1, nsp2, and nsp11,
target different parts of the host cellular immune system and
their synergistic effect during the course of infection could
be able to shut down the host cell innate immune response
completely.This may explain why the induction of interferon
and some immunomodulatory cytokines are inhibited during
in vivo EAV infection [62].
Among the three potential IFN antagonists of EAV,
expression of nsp1 had the strongest inhibitory effect on
IFN-𝛽 promoter activation. In comparison to our findings,
previous studies on PRRSV also demonstrated that the
EAV nsp1 homologous, PRRSV nsp1𝛼/𝛽 has the strongest
ability to inhibit type I IFN synthesis [26, 31, 51, 63–67].
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Figure 6: Effect of EAV nsp1 in IRF-3 and NF-𝜅B nuclear translocation. (a) HeLa cells were transfected with FLAG-tagged EAV nsp1 for 12 h
and cells were stimulated with poly(I:C) (1 𝜇g/mL) for 8 h. Cells were fixed and stained with rabbit anti-IRF-3 Ab for endogenous IRF-3 and
mouse anti-FLAGAb for FLAG-tagged EAV nsp1, followed by incubation with Alexa Fluor 594-conjugated (red) and 488-conjugated (green)
secondary antibodies, respectively, along with DAPI for nucleus staining (blue). (b) HeLa cells were transfected with FLAG-tagged EAV nsp1
for 12 h and subsequently treated with 20 ng/mL of TNF-𝛼 for 45min or untreated. Cells were then costained with mouse anti-FLAG MAb
for FLAG-tagged EAV nsp1 and rabbit anti p65 polyclonal antibody for endogenous NF-𝜅B p65 subunit followed by Alexa Fluor 488-labeled
(green) anti-mouse Ab and Alexa Fluor 594-labeled (red) anti-rabbit Ab, respectively, along with DAPI for nucleus staining (blue).
Further analysis revealed that EAV nsp1 inhibited two key
signaling pathways for IFN-𝛽 activation, the IRF-3- and NF-
𝜅B-dependent signaling pathways. In our study, EAV nsp1
blocked each signaling step upstream of IRF-3 or NF-𝜅B acti-
vation, suggesting that EAVnsp1 acts downstream of all those
tested steps in both signaling pathways. Immunofluorescence
microscopy analysis further showed that nsp1 did not have
much effect on the nuclear accumulation of IRF-3 and NF-
𝜅B. Therefore, we postulated that EAV nsp1 might have an
effect on the IFN-𝛽 promoter inside the nucleus. Previous
studies have shown that PRRSV nsp1𝛼/𝛽 modulates type I
IFN response by blocking dsRNA-induced IRF-3 activation
and IFN promoter activities, but IRF-3 phosphorylation and
its nuclear translocation occur normally in the presence of
the nsp1𝛼/𝛽 [51]. Recent study reported that PRRSV nsp1𝛼
blocks the IRF-3 activation by degrading the CREB (cyclic
AMP response element binding)-binding protein (CBP) and
subsequently inhibiting formation of enhanceosomes in the
nucleus [51, 63]. EAV nsp1 was reported to be largely nuclear
located, similar to PRRSV nsp1𝛽 [68], suggesting that it
may have an effect on the formation of the transcription
enhanceosome on the IFN-𝛽 promoter inside the nucleus.
However, PRRSV nsp1𝛽 does not degrade CBP or interrupt
the formation of enhanceosome [68]. Thus, EAV nsp1 may
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have a unique function in modulating the IFN production in
the nucleus. The EAV nsp1 does not contain the traditional
nuclear localization signal [68], which suggests that nsp1
might be bound with cellular protein(s) and shuttled into
the nucleus. Further studies are required to map the exact
point(s) on the IFN induction pathway at which EAV nsp1
acts. It will be interesting to determine the requirement
for nuclear localization of the EAV nsp1 that relates to its
interferon antagonist function.
In summary, this study is the first report on molecular
mechanisms of EAV involved in IFN antagonistic activity
in its natural host cells. Our data indicate that several EAV
replicase proteins, including nsp1, nsp2, and nsp11, possess
IFN antagonistic activity and may have potential roles in the
regulation of host innate immune responses. Among these
proteins, nsp1 may play a key role as IFN antagonist. Further
studies are needed to elucidate the detailed mechanisms that
EAV proteins are involved in counteracting the host innate
immune response.
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